down arrow

Astria Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04635X1028
USD
12.98
0.06 (0.46%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

12.8613.04

52 Week

3.5613.29
Valuation
Technical
Day's Volume

CASH

212.7 k

Shareholding (Jun 2025)

FII

15.26%

Held by 58 FIIs

DII

34.87%

Held by 36 DIIs

Promoter

21.20%

How big is Astria Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Astria Therapeutics, Inc. has a market capitalization of 321.68 million, with net sales of 0.00 million and a net profit of -108.04 million over the latest four quarters. Shareholder's funds are 319.26 million, and total assets amount to 342.36 million.

As of Jun 18, Astria Therapeutics, Inc. has a market capitalization of 321.68 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -108.04 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 319.26 million and Total Assets of 342.36 million.

Read More

What does Astria Therapeutics, Inc. do?

22-Jun-2025

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics, with a market cap of USD 321.68 million and a recent net profit of -34 million. The company has no dividend yield and negative financial metrics, including a debt equity ratio of -1.02 and a return on equity of -37.35%.

Overview: <BR>Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics in the Pharmaceuticals & Biotechnology industry, with a market cap of USD 321.68 Million.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 321.68 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -37.35% <BR>Price to Book: 1.11<BR><BR>Contact Details: <BR>Address: 100 High Street, 28th Floor, BOSTON MA : 02110 <BR>Tel: 1 617 3491971 <BR>Fax: 1 617 2732637 <BR>Website: http://www.catabasis.com/

Read More

Who are in the management team of Astria Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Astria Therapeutics, Inc. includes Independent Chairman Kenneth Bate, CEO and Co-Founder Dr. Jill Milne, and Independent Directors Dr. Burt Adelman, Dr. Joanne Beck, Mr. Hugh Cole, Mr. Michael Kishbauch, and Mr. Gregg Lapointe. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Astria Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Kenneth Bate, who serves as the Independent Chairman of the Board.<BR>- Dr. Jill Milne, who is the President, Chief Executive Officer, Co-Founder, and a Director.<BR>- Dr. Burt Adelman, serving as an Independent Director.<BR>- Dr. Joanne Beck, also an Independent Director.<BR>- Mr. Hugh Cole, who is an Independent Director.<BR>- Mr. Michael Kishbauch, serving as an Independent Director.<BR>- Mr. Gregg Lapointe, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Astria Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Astria Therapeutics, Inc. shows a mildly bullish trend supported by positive indicators on shorter timeframes, but it has significantly underperformed the S&P 500 with a -35.57% return over the past year.

As of 12 September 2025, the technical trend for Astria Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe, bullish Bollinger Bands on the weekly, and a bullish daily moving average. However, the monthly MACD and KST are bearish, indicating some weakness in longer-term momentum. The Dow Theory also reflects a mildly bullish outlook on both weekly and monthly bases. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a -35.57% return over the past year compared to the S&P's 17.14%, and a significant -82.19% over the last five and ten years.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 419 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-44.88%

stock-summary
Price to Book

1.61

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-33 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
74.23%
0%
74.23%
6 Months
131.37%
0%
131.37%
1 Year
36.34%
0%
36.34%
2 Years
91.16%
0%
91.16%
3 Years
-12.3%
0%
-12.3%
4 Years
135.57%
0%
135.57%
5 Years
-9.1%
0%
-9.1%

Astria Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-217.47%
EBIT to Interest (avg)
-65.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.17
EV to EBIT
-0.36
EV to EBITDA
-0.36
EV to Capital Employed
-10.13
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-37.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 35 Schemes (28.67%)

Foreign Institutions

Held by 58 Foreign Institutions (15.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -36.78% vs -92.06% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-35.80",
          "val2": "-28.80",
          "chgp": "-24.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.10",
          "val2": "-24.20",
          "chgp": "-36.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -29.36% vs -40.73% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-111.60",
          "val2": "-67.80",
          "chgp": "-64.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-15.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-94.30",
          "val2": "-72.90",
          "chgp": "-29.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-35.80
-28.80
-24.31%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-33.10
-24.20
-36.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -36.78% vs -92.06% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-111.60
-67.80
-64.60%
Interest
0.00
0.00
Exceptional Items
0.00
-15.20
100.00%
Consolidate Net Profit
-94.30
-72.90
-29.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -29.36% vs -40.73% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Astria Therapeutics, Inc. stock-summary
stock-summary
Astria Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to edasalonexent, the Company has developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. The Company’s Safely Metabolized and Rationally Targeted (SMART) is a linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Company Coordinates stock-summary
Company Details
100 High Street, 28th Floor , BOSTON MA : 02110
stock-summary
Tel: 1 617 34919711 617 3491971
stock-summary
http://www.catabasis.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."